Recurrent Pregnancy Loss in Maharashtra: Causes, Diagnosis & Path to a Successful Pregnancy

Recurrent Pregnancy Loss is defined by most international guidelines — including those adopted by leading fertility centres across Maharashtra — as two or more clinically confirmed pregnancy losses before 20 weeks of gestation. Some clinicians begin investigation after two losses, particularly if the woman is over 35, though three consecutive losses remain the traditional threshold for formal RPL protocols.

It is important to distinguish RPL from infertility: couples with RPL can achieve pregnancy, sometimes naturally, but the pregnancies do not progress. This distinction matters enormously for treatment planning. In Mumbai and Pune fertility clinics, RPL patients are increasingly managed by dedicated recurrent-loss teams rather than general gynaecologists, reflecting growing recognition that RPL is a complex, multi-factorial condition.

The HomeIVF Medical Board emphasises that RPL should never be dismissed as 'bad luck' after a second loss. A structured, systematic investigation gives couples in Nagpur, Thane, and smaller Maharashtra districts equal access to the same diagnostic rigour previously available only in metro centres — without requiring repeated hospital visits for every test or consultation.

Understanding why RPL occurs is the first step toward preventing it. Causes are broadly grouped into genetic, anatomical, endocrine, immunological, thrombophilic, and unexplained categories — and in many Maharashtra patients, more than one factor is present simultaneously.

Genetic causes are the most frequent: random chromosomal errors in embryos (aneuploidy) account for the majority of first-trimester losses. In 2–5% of RPL couples, one or both partners carry a balanced chromosomal translocation — a structural rearrangement that produces no health issues for the carrier but significantly increases miscarriage risk in offspring.

Uterine structural abnormalities — septate uterus, fibroids distorting the cavity, Asherman's syndrome — are found in 10–15% of RPL patients investigated in Pune and Mumbai fertility units. Hormonal factors such as poorly controlled thyroid disease, elevated prolactin, and undiagnosed PCOS are highly prevalent in Maharashtra's urban and semi-urban populations. Antiphospholipid syndrome (APS), an autoimmune clotting disorder, is detected in 10–15% of RPL cases and is one of the most actionable diagnoses because it responds well to low-dose aspirin and heparin therapy. Unexplained RPL — where no cause is found despite full workup — still carries a favourable outlook with supportive care.

The most visible symptom of RPL is recurrent vaginal bleeding and cramping in early pregnancy, typically between 6 and 12 weeks, though losses can occur later. However, many patients experience 'missed miscarriages' — where the embryo stops developing without immediate bleeding — detected only on ultrasound. This pattern is particularly distressing because the body has not yet responded, and couples in cities like Nashik or Thane may receive the news during a routine scan with little immediate support infrastructure around them.

Beyond the physical, RPL presents with anxiety, depression, anticipatory grief in subsequent pregnancies, and relationship strain. These psychological symptoms are as clinically significant as the physical ones and should be addressed alongside medical investigation.

You should seek a formal RPL consultation after a second pregnancy loss, without waiting for a third, if: you are over 35; a structural uterine issue has been previously noted; you have a known autoimmune or clotting disorder; or either partner has a family history of chromosomal conditions. HomeIVF's care coordinators in Maharashtra can facilitate same-week specialist consultations, removing the typical 4–8 week wait common at busy Mumbai and Pune hospital outpatient departments.

A thorough RPL workup follows a logical sequence. The HomeIVF Medical Board recommends initiating investigation 6–8 weeks after the most recent loss to allow hormonal levels to normalise. Tests are divided into partner-specific and couple-level evaluations.

For the female partner: pelvic ultrasound and saline infusion sonography (SIS) or hysteroscopy to assess uterine anatomy; thyroid function (TSH, free T4), prolactin, fasting glucose and insulin for PCOS screening; antiphospholipid antibody panel (anticardiolipin IgG/IgM, lupus anticoagulant, anti-beta-2 glycoprotein); inherited thrombophilia screen (Factor V Leiden, prothrombin gene mutation, protein C and S, antithrombin III); and AMH to assess ovarian reserve.

For the male partner: karyotype and semen DNA fragmentation index (DFI), since elevated sperm DNA damage is an underappreciated contributor to RPL, with DFI above 25–30% associated with increased miscarriage risk.

For embryos from prior IVF cycles: preimplantation genetic testing for aneuploidy (PGT-A) can be added to future cycles.

In Maharashtra, many of these blood tests are now available at accredited diagnostic chains in Nagpur and Nashik, and HomeIVF coordinates sample collection at home, digital report sharing, and specialist interpretation — eliminating the logistical burden on grieving couples.

Treatment for RPL is entirely cause-driven, which is why accurate diagnosis is non-negotiable. For couples where APS is confirmed, a combination of low-dose aspirin (75 mg daily) started pre-conceptionally and low-molecular-weight heparin after a positive pregnancy test reduces miscarriage rates significantly — this protocol is well-established and widely available across Maharashtra.

Uterine structural corrections are highly effective: hysteroscopic resection of a uterine septum, removal of submucosal fibroids, or lysis of intrauterine adhesions in Asherman's syndrome are performed as day procedures at accredited centres in Mumbai and Pune, with subsequent pregnancy success rates of 70–85% in selected patients.

For couples with thyroid dysfunction or hyperprolactinaemia, normalising these hormones before the next conception cycle dramatically improves outcomes. PCOS-related RPL responds to metformin, weight optimisation, and ovulation induction protocols.

For couples with chromosomal translocations or repeated unexplained losses, IVF with PGT-A allows the selection of chromosomally normal embryos before transfer, bypassing the most common cause of miscarriage. HomeIVF offers end-to-end IVF packages starting from ₹1.5 lakh, with protocols personalised to RPL patients — including luteal phase support, progesterone supplementation, and early-pregnancy monitoring that continues week by week after transfer.

For unexplained RPL, the evidence supports a 'tender loving care' (TLC) approach — structured early-pregnancy surveillance with weekly scans and supportive consultations — which itself improves live birth rates by 10–15% compared with expectant management alone.

HomeIVF was built specifically for couples who need consistent, senior-specialist-level care without the constraints of hospital geography. For RPL patients in Maharashtra — whether in a Thane apartment or a Nagpur suburb — this means blood draws at home, digital prescription delivery, AI-powered cycle tracking, and video consultations with fertility specialists reviewed by the HomeIVF Medical Board, all coordinated through a single app.

A dedicated RPL care pathway at HomeIVF includes: an intake questionnaire capturing all prior pregnancy histories; a curated diagnostic panel dispatched within 48 hours; a specialist interpretation call within 7 days; a written personalised protocol; and ongoing support through a named care coordinator who remains consistent throughout the journey.

For patients who have previously felt dismissed at busy OPDs in Pune or Mumbai — told to 'try again' without investigation — HomeIVF offers a validating, evidence-driven alternative. The platform does not replace senior specialists; it delivers senior-specialist care in the patient's own environment, reducing the physical and emotional overhead of repeated hospital visits. Couples in semi-urban Maharashtra districts where subspecialty RPL clinics do not exist locally now have access to the same standard of care as their counterparts in metropolitan centres.

Financial transparency is critical for RPL patients, who may have already spent significantly on prior pregnancies and losses. The cost of an RPL diagnostic workup in Maharashtra varies: a complete panel including karyotyping, antiphospholipid antibodies, thrombophilia screen, and uterine imaging typically ranges across accredited labs and imaging centres, with HomeIVF coordinating bundled pricing for home-collection packages.

Timelines matter too. A realistic RPL investigation and initial treatment plan in Maharashtra runs as follows: weeks 1–2 for sample collection and imaging; weeks 3–5 for specialist review and protocol design; weeks 6–8 for medical intervention (if indicated) or preparation for the next conception attempt. If IVF with PGT-A is recommended, the full cycle adds another 6–8 weeks.

HomeIVF's care coordinators help Maharashtra couples navigate CGHS, ESIS, and corporate insurance panels — many of which cover diagnostic tests for RPL even when IVF itself is excluded. Pre-authorization guidance is provided as part of onboarding. This financial counselling component is especially valued by patients in Nashik and Nagpur, where fertility subspecialty billing practices are less standardised than in Mumbai or Pune, and couples often pay more for less coordinated care.

Maharashtra presents a striking paradox: it is home to some of India's most advanced fertility infrastructure — concentrated in South Mumbai, Baner in Pune, and Dharampeth in Nagpur — yet large populations in Thane's peripheral areas, Nashik's rural belt, and Vidarbha towns remain underserved. The barriers are structural, cultural, and logistical.

Structural barriers include long wait times at tertiary referral hospitals, shortage of RPL subspecialists outside major cities, and fragmented records — a couple may have sonography in one clinic, blood tests in another, and genetic counselling at a third, with no single clinician synthesising the picture.

Cultural barriers are significant: in many Maharashtra communities, repeated miscarriage carries stigma, blamed on the woman's constitution or fate, discouraging formal medical consultation. Male partners rarely attend fertility consultations, meaning male-factor contributors like sperm DNA fragmentation go uninvestigated for years.

Logistical barriers hit hardest: working couples in Mumbai with demanding commutes genuinely cannot afford multiple mid-week clinic visits. HomeIVF dissolves these barriers by centralising care digitally, normalising male-partner testing as a standard intake component, and providing Marathi-language communication options for patients less comfortable in English or Hindi. The HomeIVF Medical Board continuously updates protocols to reflect the latest ESHRE and ASRM RPL guidelines, ensuring Maharashtra patients receive globally benchmarked care locally delivered.